Fast to Market — The Coming Challenges for Pharma–Production

Related Vendors

TURCK GmbH

TRM Filter d.o.o.

Frewitt fabrique de machines SA

NNE GmbH

As new pharmaceutical products get approved faster, the need for agility and flexibility in pharmaceutical manufacturing will increase. Needless to say, time-to-market will again become a key driver in pharmaceutical operations, following a long period where consolidation, effectiveness and cost-cutting were on top of the agenda. For the most innovative pharmaceutical companies and for their business partners, the ability to respond to the faster approvals will require new thinking.

Some companies have tried it before, but not many. The industry average for a new facility or adapting a facility to a new product is still several years and sometimes longer than the available time to get a new product to the market. So, if you work in pharmaceutical manufacturing of the most innovative companies or in their partner companies, for example in contract manufacturing, be prepared for new manufacturing approaches that cut down time-to-market. Faster approval of new break-through drugs is an important part of the new pharmaceutical agenda.

Automation/Image Processing

How to save Costs through Automatic Granulate Inspection

Is Pharmaceutical Manufacturing Reaaly Ready for the Change?

The question is, however, whether manufacturing operations are ready for this change. How do you re-store agility in an industry that for many years had habits from a time where operational excellence and agility were not a part of the daily vocabulary? Where do you find the inspiration and the solutions? How fast could you bring a new product to market, if you have to? Most of today’s pharmaceutical facilities were designed and equipped for the philosophies of the blockbuster era. Some of the facilities have been upgraded and re-vamped to prepare for the future product pipeline. The question is whether these upgraded facilities point towards the “facilities of the future” or if they will just remain an intermediate stage in a transformation of manufacturing. No matter whether you choose to upgrade or to re-think manufacturing in your company, the big question is how fast you and your company can get ready to new time-to-market challenges and opportunities?

Gert Moelgaard is Head of Strategic Development in NNE Pharmaplan.

(ID:42541757)